ERBB2 and neoplasm: A 213Bi-labeled RIC targeting HER-2/neu receptors did not eradicate tumors but was more effective than 213Bi-labeled control RICs at prolonging survival and inhibiting tumor growth in subcutaneous and metastatic breast cancer models [19].